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Objectives: Our study sought to elucidate the role of oxidative stress for shedding of tumor necrosis factor-a (TNF-a) and for activating
TNF-a-converting enzyme (TACE). Background: TNF-a, a central inflammatory cytokine, is discussed as one of the mediators of
reperfusion injury. Shedding of membrane-bound pro-TNF-a is thought to be largely due to TNF-a-converting enzyme (TACE). Methods:
Release of TNF-a and TACE dependency were studied in isolated rat hearts and in the human mast cell line HMC-1. Results: In reperfused
hearts, interstitial release of TNF-a occurred in two phases (2–10 and >45 min). It depended on the presence of oxygen during reperfusion
and was attenuated by reduced glutathione. Infusion of the oxidants H2O2 or HOCl elicited release in non-ischemic hearts. TNF-a release
was inhibited in hearts treated with degranulation inhibitors ketotifen or cromoglycate, suggesting mast cells as major source for myocardial
TNF-a. This was confirmed by tissue staining. Post-ischemic release of histamine, however, did not parallel that of TNF-a. Heart tissue
contained mainly mature TACE. HMC-1 expressed abundant pro-TACE and cleaved the pro-TNF-a-peptide Ac-SPLAQAVRSSSR-NH2.
However, cleavage was nonspecific and only partly inhibited by TACE inhibitor TAPI-2 (10–100 Amol/l), while it was stimulated by H2O2
and HOCl and fully blocked by the nonspecific metalloprotease inhibitor o-phenanthroline. Conclusions: The mechanism underlying TNF-a
release from post-ischemic myocardium is oxidation-dependent but largely independent of activation of TACE. Mast cell stabilizers may be
useful in preventing TNF-a release during reperfusion.
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HCOCH2CH(CH2CH(CH3)2CO-t-Butyl-Gly-Ala-NHCH2CH2NH2; KHB,
Krebs–Henseleit buffer; GSH, reduced glutathione; HMC-1, human mast
cell line-1; CABG, coronary artery bypass grafting; DSCG, disodium
cromoglycate
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(B.F. Becker).leukocytes and degranulation of resident mast cells, with
sequelae such as edema formation and tissue remodelling.
Acute release of a number of proinflammatory cytokines,
such as interleukines (IL-1, -6, -8) and tumor necrosis factor-
a (TNF-a), has been demonstrated in reperfused myocardi-
um of man and of various animal species [1–4]. Enhanced
levels of TNF-a, for example, have been found in blood from
the coronary sinus of patients undergoing CABG [1]. Al-
though negative inotropic [5] and proinflammatory [6] as
well as some cytoprotective effects [7] have been proposed
for TNF-a, the role of the cytokine in reperfusion injury is
controversial. Also, the cellular source and the mechanism of
release of myocardial TNF-a are still rather speculative.
Proteolytic cleavage of the 26-kDa membrane-bound
precursor pro-TNF-a yields the soluble, systemically active,ed by Elsevier B.V. All rights reserved.
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 17-kDa cytokine. This ‘‘membrane shedding’’ is thought to
be mainly accomplished by TNF-a-converting enzyme
(TACE/ADAM17) [8], a metalloproteinase of the ADAM
superfamily [9]. TACE is synthesized as proenzyme, in
which a cysteine residue (Cys-184) within the prodomain
interacts via its SH-group with the catalytic site Zn2 +,
inhibiting the proteolytic function [10]. This ‘‘cysteine
switch’’ has been identified for many members of the
ADAM and MMP families [11,12]. A postulated mechanism
of TACE activation is via proteolytic removal of the entire
prodomain, presumably by a furin-like activity [13]. A
different mechanism might involve oxidation of the SH-
group of the inhibitory cysteine, as already described for
some MMPs [14]. Recent evidence suggests that, under
certain circumstances, pro-TACE can be activated in a
similar fashion by reactive oxygen species [15].
Since different oxidants and reactive oxygen species
(ROS) are generated in reperfused ischemic tissue [16],
we hypothesized that an acute oxidative activation of TACE
during reperfusion might be responsible for the post-ische-
mic release of TNF-a from myocardial tissue. at U
niversitaetsbibliothek M
uenchen on January 24, 2013
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2.1. Reagents
The peptides Ac-Ser-Pro-Leu-Ala-Gln-Ala-Val-Ser-Ser-
Ser-Arg-NH2 (TNF-a-peptide) and Ac-Ser-Pro-Leu-Ala-
Gln-Ala were synthesized by Biosource (Nivelles, Belgium).
The TACE inhibitor N-(R)-(2-(hydroxyaminocarbonyl)-
methyl)-4-ethylpentanoyl-L-t-butyl-Gly-L-alanine-2-ami-
noethylamide (TAPI-2) was purchased from Peptides
International (Louisville, USA). Ketotifen, disodium cromo-
glycate and ortho-phenanthroline were supplied by Sigma
(Taufkirchen, Germany); + CompleteR protease inhibitor
cocktail by Roche Diagnostics (Mannheim, Germany). The
primary anti-TACE antibody for Western blotting was a
rabbit polyclonal antibody against a peptide corresponding
to amino acids 807–823 of human TACE C-terminus
(Chemicon International, USA). Antibodies for colocaliza-
tion of TACE and TNF-a in rat ventricular tissue were (i) an
affinity-purified goat polyclonal antibody (C-15) against a
recombinant peptide of human TACE C-terminus (Santa
Cruz Biotechnology, USA) and (ii) a rabbit monoclonal
antibody against rat TNF-a (Endogen, Woburn, USA);
secondary antibodies for immunofluorescence were (i) Alex-
aFluor-488-coupled anti-goat and (ii) AlexaFluor-546-cou-
pled anti-rabbit antibody (Molecular Probes, Eugene, USA).
All other reagents used were of analytical grade quality and
supplied by Merck (Darmstadt, Germany).
2.2. Cell culture
HMC-1 cells [17] were maintained in ISCOVE’s medium
(Biochrom, Berlin, Germany) plus 10% iron-supplementedFBS, 1.2 mmol/l monothioglycerol and 10 Ag/ml gentamy-
cin (all from Sigma).
2.3. Animals
The investigation conforms with the Guide for the Care
and Use of Laboratory Animals published by the US
National Institutes of Health (NIH Publication No. 85-23,
revised 1996).
2.4. Perfusion of isolated rat hearts
Male Wistar rats (body weight 300–500 g) were
anesthetized with ether and killed by incision into the
carotid arteries. Hearts were rapidly excised and perfused
via an aortic cannula at 100 cm H2O in a Langendorff-
mode with a modified KHB (pH 7.4, 5.6% CO2/94.4%
O2). The pulmonary, caval and azygal veins were ligated
and a cannula was inserted into the pulmonary artery.
After an equilibration period of 30 min, ischemic control
hearts were subjected to 15 min of global ischemia
(immersed in Tyrode’s buffer at 37 jC) and reperfused
(5.6% CO2/94.4% O2) for 120 min. A subset of hearts was
treated similarly except for the presence of 100 Amol/
l reduced glutathione (GSH) in the perfusate throughout.
The group termed ‘‘anoxia hearts’’ was subjected to 15
min of global ischemia, and then reperfused in the absence
of oxygen (5.6% CO2/94.4% N2) for 90 min. Longer
anoxic peperfusion was not meaningful, because contrac-
tility declined markedly after 90 min. ‘‘Low-flow hearts’’
underwent 15 min of global ischemia and then 120 min of
reperfusion (5.6% CO2/94.4% O2) at a constant, low rate
of flow of 1 ml/min (normal: 4–6 ml/min). Time control
hearts were not subjected to ischemia. Infusions of 100
nmol/l ketotifen or 10 Amol/l DSCG were initiated 30 or
15 min prior to ischemia, respectively, in two subset of
hearts and continued throughout reperfusion. Further sub-
sets of hearts received an infusion of oxidants (10 min 1
AM HOCl or 30 min 100 AM H2O2) instead of undergoing
ischemia.
2.5. Immunodetection of TNF-a and histamine
Transudate (i.e., interstitial/lymphatic fluid appearing at
the epicardial surface) was collected quantitatively from the
apex of the heart over periods of 60–90 s at various points
of time and snap-frozen in liquid nitrogen. Sample aliquots
were analyzed by ELISA according to the manufacturer’s
protocols (TNF-a: rat TNFa ultrasensitive, Biosource; his-
tamine: Beckman Coulter Bioresearch, Krefeld, Germany).
Release of TNF-a and histamine from myocardial tissue
was calculated for each time point by multiplication of the
respective concentration and flow rate values (collected
weight/sampling time) of transudate. Aliquots of coronary
venous effluent were collected from the cannulated pulmo-
nary artery and similarly analysed.
lar Research 60 (2003) 608–616
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 2.6. Quantitation of TNF-a mRNA by RT-PCR
About 200 mg of frozen ventriclular tissue was homog-
enized by pestle in liquid nitrogen, and 2 ml of Trizolk
reagent (Life Technologies) was added. Total RNA (5 Ag)
was reverse-transcribed using 20U of RevertAidk M-
MuLV Reverse Transcriptase (MBI Fermentas). A 5-
Al aliquot of the resulting cDNA then underwent PCR using
a CytoXpress quantitative PCRn Detection Kit (Biosource).
The thermocycler profile was: (1 min 96j/4 min 58 jC) 2;
(1 min 94 jC/2.5 min 58 jC) 30; 10 min 70 jC. The
ethidium bromide-stained PCR products were visualized by
means of a UV transilluminator (Biorad, Germany) on a 2%
agarose gel.
2.7. Immunohistochemical staining of rat ventriclular tissue
Isolated hearts were perfusion-fixed for 2 min with 1%
formaldehyde in PBS at a flow rate of 4 ml/min. Staining of
paraffin-embedded tissue slices for the presence of mast cells
and TNF-a was performed as described before [18]. Coloc-
alization of TNF-a and TACE was investigated by immu-
nofluorescence (for antibodies, see Section 2.1) and confocal
microscopy (Zeiss LSM 410, Zeiss, Oberkochen, Germany).
Samples were inspected with a 63 oil immersion lens, and
illuminated with 488 and 543 nm laser, respectively. A 510–
525 nm bandpass and a 570 nm longpass served as emission
filters. The size of the pinhole was 20 throughout.
2.8. Preparation of heart tissue homogenates
Hearts were snap-frozen in liquid nitrogen using pre-
cooled aluminium tongs. About 175 mg of frozen material
was homogenized, first by pestle and then glass homogenizer
in cold homogenization buffer (50 mM Tris–HCl; 1 mM
DTT; 100 AM o-phenanthroline; 0.2% Nonidet P-40; pH 7.4)
supplemented with CompleteR protease inhibitor cocktail.
Samples were spun at 3900 g at 4 jC for 30 min and the
supernatants collected.
2.9. Lysis of HMC-1 for Western blot
About 106 cells were lysed at 4 jC in 200 Al of lysis buffer
(20 mM KH2PO4; 1 mM EDTA; 1 mM PefaBlock; 1 AM
leupeptin; 1 AM pepstatin; 50 mM NaF; 40 mM Na4P2O7; 1
mM Na3VO4; 1 mM o-phenanthroline; plus CompleteR
protease inhibitor cocktail). HMC-1 cell lysates were centri-
fuged at 12,000 g for 5 min, the pellets discarded and the
supernatants collected.
2.10. Determination of TACE protein by Western blotting
Samples (supernatant of heart homogenates and HMC-1
lysates) were boiled for 7 min with 1/4 volume of 4
loading buffer (250 mM Tris–HCl, pH 6.8; 8% SDS; 40%
glycerol; 0.02% bromophenol blue; 400 mM mercaptoetha-
S. Gilles et al. / Cardiovascu610nol), and defined amounts of protein were loaded on 8%
SDS polyacrylamide gel. For blotting after electrophoresis,
primary (1:1000) and secondary antibodies were diluted in
3% dry milk powder in PBS. The immunoreactive proteins
were visualized by chemiluminescence.
2.11. TNF-a-peptide cleavage assay with HMC-1 cells
Cells (107) were washed 1 with calcium-free PBS and
were then resuspended in 1 ml PBS. Incubation with 17 AM
of the TNF-a-peptide Ac-SPLAQAVRSSSR-NH2 occurred
at 37 jC in cylindrical cups on a rotating device. To compare
specificity of cleavage, TNF-a-peptide was also incubated
with recombinant human TACE catalytic domain. Disap-
pearance of the original substrate as well as the cor-
responding appearance of Ac-SPLAQA, one of the two
TACE-specific cleavage products, were monitored by
HPLC. Ninety-five to one hundred percent inhibition of
degradation by recombinant TACE was achieved with the
drug TAPI at concentrations of about 1 Amol/l (IC50: 0.01
Amol/l, data not shown).
2.12. HPLC analysis
Cells were lysed by adding 4N HClO4 to the suspen-
sion (volume ratio 1:10) and vortexing immediately. Incu-
bated rhTACE was treated similarly with HClO4. High-
pressure liquid chromatography (HPLC) was used to
simultaneously quantify the 12-amino-acid peptide sub-
strate of TACE (Ac-SPLAQAVRSSSR-NH2) and the 6-
amino-acid fragment Ac-SPLAQA in the acidic extracts.
The conditions used were as follows: C18-AquaR column
(Phenomenex, Aschaffenburg, Germany), isocratic elution
with 32% HClO4 (pH 2) in methanol (41%) and water
(27%), peak detection at 200 nm (L-7400 detector, Hita-
chi-Merck, Darmstadt, Germany). Retention times at a flow
rate of 1 ml/min were 10.1 min for Ac-SPLAQAVRSSSR-
NH2 and 15.9 min for Ac-SPLAQA.
2.13. Statistical methods
The sample size of each experimental group is given
in the results section. TNF-a release from hearts is
expressed as meanF S.E.M., all other data as meanF
S.D. Data from two independent populations were ana-
lysed for significant differences using Student t-test (nor-
mally distributed data) or Mann–Whitney rank sum test
(nonnormal distribution). To test for significant differences
between data of two treatment groups at a given point of
time, two-way repeated measures ANOVA was performed.
In the case of significant differences, the post hoc
Student–Newman–Keuls multiple comparison procedure
was applied. Differences were considered statistically sig-
nificant if pV 0.05. All calculating procedures were carried
out by the statistical software SigmaStatk, version 1.0
(Jandel).
Fig. 2. (A) Mean TNF-a release (F S.E.M.) of ischemic rat hearts
reperfused with different protocols. GSH= perfusate augmented with 100
Amol/l reduced glutathione. *Significant vs. pre-ischemic value. #Signifi-
cant vs. ischemic control hearts. (B) Mean TNF-a release (F S.E.M.) of
perfused rat hearts treated with oxidants. *Significant vs. pre-ischemic
value. #Significant vs. time control hearts.
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 3. Results
3.1. Isolated rat hearts release TNF-a into the interstitium
after ischemia
Of the two myocardial fluid compartments (coronary
effluent and transudate), only the interstitial transudate
collected at the epicardial surface contained detectable
amounts of TNF-a. This finding corresponds to previous
results obtained with rat hearts. While control hearts release
at most 3 pg/min TNF-a into the transudate at the end of a
perfusion period of 180 min, hearts that underwent 15 min of
global ischemia produce up to 50 pg/min TNF-a during 2
h of aerobic reperfusion (Fig. 1). In these hearts, TNF-a
release displays an early peak 2–10 min after the onset of
reperfusion, decreases and then rises again until 120 min
after ischemia. Pertinently, almost no TNF-a mRNA is
found in pre-ischemic heart tissue, while after 1 h of reper-
fusion, transcription of the cytokine gene is enhanced (Fig. 1,
insert).
3.2. Oxidative stress is required for the post-ischemic
release of TNF-a
A group of hearts was equilibrated in the presence of the
antioxidant GSH (100 Amol/l), then underwent global
ischemia and was finally reperfused again in the presence
of GSH. In this group, both the early and the late release of
TNF-a were reduced, although the late (60–120 min) post-
ischemic TNF-a release still differed significantly from the
mean pre-ischemic value (Fig. 2A). Two further groups of
ischemic hearts were subjected to modified reperfusion
protocols: one was reperfused with KHB gassed with 95%
N2, instead of with 95% O2 as in the ischemic control group,
the other was reperfused with oxygen-gassed buffer but at aFig. 1. TNF-a in transudate of rat hearts. Depicted are mean values
(F S.E.M.). *Significant vs. pre-ischemic values. #Significant vs. time
control hearts. Insert: RT-PCR of total RNA isolated from pre-ischemic
(lane 1) and post-ischemic hearts reperfused for 1 h (lane 2), showing TNF-
a and GAPDH (glyceraldehyde-phosphate dehydrogenase) mRNA.
uenchen on January 24, 2013constant, reduced flow rate (1 ml/min compared to reperfu-
sion at constant pressure in ischemic control hearts with a
mean coronary flow of 4–6 ml/min). Post-ischemic tran-
sudates of low-flow and anoxically reperfused hearts both
contained significantly lower levels of TNF-a than transu-
dates of ischemic control hearts (Fig. 2A).
3.3. Infusion of oxidants mimics the effect of ischemia and
reperfusion
Two groups of non-ischemic hearts, after an equilibration
period of 30 min, were infused for another 30 min with 100
Amol/l H2O2 or for 10 min with 1 Amol/l HOCl, respec-
tively. Both treatment groups showed elevated TNF-a levels
as compared to the untreated control group (Fig. 2B), the
TNF-a production of hearts treated with H2O2 already being
significantly enhanced during the early phase of infusion. In
contrast, the TNF-a release of HOCl-treated hearts was not
significantly enhanced until 90 min after onset. Interesting-
ly, release continued to rise even after cessation of infusion
of either oxidant.
lar Research 60 (2003) 608–616
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 3.4. Ketotifen (100 nmol/l) or DSCG (10 lmol/l) inhibit
release of TNF-a but not of histamine
A quantitatively identical suppression of post-ischemic
release of myocardial TNF-a as seen in the absence of
oxygen was observed in the presence of the mast cell
stabilizers ketotifen or DSCG (Fig. 3A). Surprisingly, they
inhibited both early and late release of the cytokine.
Histamine, like TNF-a, was restricted to the transudate
of rat hearts, with no detectable release into the coronary
effluent (data not shown). While some hearts released
minor amounts of histamine even before ischemia, maxi-
mal levels were reached immediately after ischemia. His-
tamine was then rapidly washed out (Fig. 3B). In
transudates of hearts treated with 100 nmol/l ketotifen,
the post-ischemic histamine levels as well as the kinetics of
histamine release remained unaltered (Fig. 3B). The same
result was obtained with the degranulation inhibitor DSCG
(Fig. 3B).
S. Gilles et al. / Cardiovascu612Fig. 3. (A) Mean TNF-a release (F S.E.M.) of ischemic rat hearts perfused
in the absence or presence of ketotifen (100 nmol/l) or DSCG (10 Amol/l).
*Significant vs. pre-ischemic values. #Significant vs. ischemic control
hearts. (B) Mean histamine release (F S.E.M.) of ischemic rat hearts
perfused in the absence or presence of 100 nmol/l ketotifen or DSCG
(10 Amol/l).
Fig. 4. Immunostaining of tissue sections through rat ventricle. (A)
Immunoflourescent staining of TACE in a tissue mast cell. (B) Immuno-
fluorescent staining of TNFa in the same cell. (C) Colocalization of TACE
and TNF-a. (D) Phase-contrast image of the tissue containing the mast cell
(arrow).
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Mast cells, as detectable by Alcian blue staining, were
frequent in rat, mouse and human myocardium (data not
shown). In all three species, they exhibited a preferential
perivascular localization. In the heart, mast cells are the
major cell type showing positive staining for TNF-a (Fig. 4).
Moreover, they showed a clear colocalization of TACE and
TNF-a (Fig. 4, panels A–D). Especially bright TACE
staining appeared perinuclearly and in some granules near
the plasma membrane (Fig. 4A). The same peripheral gran-
ules also stained positive for TNF-a (Fig. 4B). Like TACE,
most of the TNF-a was concentrated in the perinuclear
space, possibly representing the trans-Golgi network.
3.6. Forms of TACE expressed in HMC-1 and rat heart
tissue
As previously reported, TACE is located at the plasma
membrane of HMC-1 [18]. In lysates of the same cells,
TACE protein is abundant (Fig. 5A, lane 1), and two
immunoreactive bands can be distinguished by Western
blotting: a larger, 100-kDa and a shorter, 80-kDa form, likely
representing the zymogen and the mature enzyme, respec-
tively. Interestingly, HMC-1 predominantly express the
unprocessed 100-kDa version of TACE.
In homogenates of rat hearts, the same two protein species
can be found, even though the overall expression is lower
than in HMC-1 lysates if normalized to the total protein
amount loaded (Fig. 5A, lanes 2 and 3). In contrast to HMC-
Fig. 6. TNF-a-peptide cleavage assay with HMC-1 cells. (A) Substrate
degradation depending on cell number and incubation time in PBS
(representative of two to three similar determinations per condition). (B)
Substrate degradation in the absence or presence of different protease/
metalloproteinase inhibitors. All incubations were carried out for 1 h at
1107 cells/ml. CON= control; CompleteR = protease-inhibitor cocktail;
phen = 1 mmol/l o-phenanthroline. (C) Stimulation of cells with oxidants.
Incubations were carried out for 1 h with 107 cells/ml PBS supplemented
with CompleteR protease inhibitor cocktail. Concentrations were 100 Amol/
l for TAPI-2, 300–500 Amol/l for H2O2 and 50 Amol/l for HOCl. Depicted
are mean values (F S.D.); #significant vs. control; *significant vs. value
without TAPI-2.
Fig. 5. TACE in Western blot of cell lysates and rat heart homogenates. (A)
Lane 1 =HMC-1 lysate, lane 2 = tissue homogenate of a heart perfused for
180 min (time control), lane 3 = tissue homogenate of a heart equilibrated
for 45 min, subjected to 15 min of ischemia and reperfused for 120 min.
Amounts of total protein loaded per lane: 50 Ag for cell lysate, 150 Ag for
heart homogenates. (B) Lanes 1 and 2 = lysates of untreated HMC-1 cells,
lanes 3 and 4 = lysates of HMC-1 cells stimulated for 1 h with 50 Amol/l
HOCl, lanes 5 and 6 = lysates of HMC-1 cells stimulated for 1 h with 1
mmol/l H2O2. Amounts of total protein loaded: 50 Ag (lanes 1, 3 and 5) or
25 Ag (lanes 2, 4 and 6). 100 kDa = pro-TACE, 80 kDa =mature TACE. All
blots are representative of at least three independent experiments.
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 1, the 80-kDa form is the prevalent one in heart tissue.
Although the intensity of the 100-kDa ‘‘immature TACE’’
band seems to decrease with ischemia/reperfusion in Fig. 5A
(cf. lanes 2 and 3), the ratio of the two bands did not differ
significantly beween homogenates of time controls and hearts
reperfused for 120 min (ratio 80 kDa/100 kDa TACE =
2.99F 0.57 and 4.30F 2.33 for time control and ischemia/
120 min reperfusion, respectively; meanF S.D., n= 4 each).
Similarly, the ratio of the two TACE bands in untreated
HMC-1 cells (about 0.6) remained the same in lysates of
cells treated for 1 hwith 50 Amol/l HOCl or 1mmol/l H2O2. A
representative Western blot is shown in Fig. 5B.
3.7. TNF-a-peptide cleaving activity of HMC-1 cells
Degradation of the peptide Ac-SPLAQA*VRSSSR-NH2
by HMC-1 cells was dependent on incubation time and cell
number (Fig. 6A). About 100% degradation was seen after 1
h in the presence of 107 cells/ml. Although the 12-mer was
readily degraded by HMC-1, there was never a trace of the
TACE-specific cleavage product Ac-SPLAQA in superna-
tants or lysates. Incubation of HMC-1 cells with Ac-
SPLAQA for up to 3 h revealed that the peptide is stable in
supernatants and is not taken up by the cells (data not shown).
Incubation of TNF-a-peptide for 1 h with 107 HMC-1
cells/ml PBS together with CompleteR inhibitor cocktail led
to an approximately 40% reduction in nonspecific peptide
degradation (Fig. 6B). A further reduction was achieved by
adding 100 Amol/l of the TACE inhibitor TAPI-2, while 10
Amol/l TAPI-2 was less effective (Fig. 6B). An almost
complete inhibition was accomplished by adding 1 mmol/l o-phenanthroline, a chelator of divalent metal ions and
universal metalloproteinase inhibitor (Fig. 6B).
Exposure of cells to oxidants (300–500 Amol/l H2O2 or
50 Amol/l HOCl) stimulated TNF-a-peptide degradation
S. Gilles et al. / Cardiovascular Research 60 (2003) 608–616614significantly (Fig. 6C). In both cases, this increase was fully
inhibitable by addition of 100 Amol/l TAPI-2 (Fig. 6C). at U
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 4. Discussion
4.1. Post-ischemic release of TNF-a depends on oxidative
stress
The acute release of TNF-a from the heart has been
observed previously in studies of patients after CABG and
in work on reperfused isolated hearts [1,6,19]. However,
neither the initiator of release nor the cellular source of the
cytokine in the heart was identified. Our initial finding now
was that ischemic rat hearts release TNF-a into the inter-
stitial fluid during early as well as late reperfusion, the early
release peaking at 2–10 min after ischemia. These rapid
kinetics of TNF-a release make this cytokine an interesting
candidate as a mediator of ischemic preconditioning [20].
The early peak could represent either a release of preformed
TNF-a from granular stores or a rapid shedding of mem-
brane-bound pro-TNF-a due to enhanced proteolytic cleav-
age. The late rise in TNF-a release, in contrast, involves de
novo synthesis of the cytokine, as seen by the up-regulation
of TNF-a m-RNA 1 h after ischemia.
The observations that ischemic rat hearts reperfused either
anoxically, under low-flow conditions or in the presence of
100 Amol/l GSH produce less TNF-a than ischemic control
hearts are strong indications of the importance of oxidative
stress. The absence of the initial TNF-a-peak in transudate of
the GSH-treated hearts suggests that rapid TNF-a release is
particularly dependent on the extracellular redox status and
that ischemia itself is not the direct trigger.
Reperfusion of ischemic tissue leads to the generation of a
variety of oxygen free radicals and oxidants [16,21]. Zhang
et al. [15] have recently demonstrated that H2O2 can activate
recombinant TACE by oxidizing the sulfhydryl group of the
inhibitory cysteine switch, and Fu et al. [14] have reported
activation of an MMP by HOCl, proposing a similar mech-
anism of interaction. In our experiments, infusion of either
HOCl or H2O2 into non-ischemic hearts led to enhanced
TNF-a production as compared to untreated non-ischemic
hearts. These results demonstrate that oxidants, even without
ischemia, suffice to mediate release of TNF-a from myocar-
dial tissue. Protracted up-regulation may occur via NFnB
(intracellular redox stress); for early release, enhanced mast
cell degranulation or acute activation of TACE and/or related
metalloproteinases seem likely mechanisms (extracellular
redox stress).
4.2. Role of mast cells
Immunohistochemical staining of rat hearts revealed
TNF-a in high concentration localizing to perivascular mast
cells. Similar localizations were found in tissue sections of
human and mouse hearts (unpublished data). The proposedrole of cardiac mast cells for post-ischemic release of TNF-a
[4,7] could largely be confirmed in our model for ischemia/
reperfusion. Notwithstanding, additional sources for TNF-a
in the heart cannot be ruled out strictly by tissue staining.
Besides CD68+ tissue macrophages bearing TNF-a (results
not shown), the cytokine might also be shed from cardiac
myocytes, especially in hearts subjected to prolonged in-
flammatory stimulation [22,23].
Immunostaining of rat ventricle revealed that TNF-a of
mast cells is lost within 10 min of reperfusion (unpublished
data). Accordingly, at least in cardiac mast cells, a mecha-
nism must exist by which TNF-a is rapidly released
following reperfusion. The observed inhibition of early
release by ketotifen or DSCG, at first sight, supports a role
of degranulation. In contrast to TNF-a release, however,
histamine release was not influenced by treatment with
ketotifen or DSCG at the chosen concentrations.
There is evidence in the literature that the concentration of
100 nmol/l ketotifen, while fully sufficient to prevent release
of TNF-a in our experiments, might simply not be high
enough to inhibit discharge of the histamine granules [24].
Interestingly, ketotifen has been reported as an inhibitor of
TNF-a release from peripheral blood mononuclear cells
(PBMCs) and was successfully used on HIV-infected
patients to treat malnutrition [25]. Furthermore, it has been
shown to be beneficial in the treatment of some forms of
physical urticaria (PU), where ketotifen reduced both cuta-
neous and serum expression of TNF-a in patients [26].
Additionally, a protective effect has been assigned to keto-
tifen in a model of experimental inflammation in the small
intestine held to mimic Crohn’s disease and which may
involve TNF-a [27].
The fact that myocardial release of histamine in our model
was also not suppressed by 10 Amol/l DSCG further supports
the hypothesis that release of TNF-a and histamine from
mast cells during early reperfusion are unlinked processes.
While the post-ischemic TNF-a release is clearly triggered
by reperfusion, histamine is already released in substantial
amounts by mast cells during ischemia, leading to elevated
histamine levels in the interstitium [28] and allowing rapid
washout during reperfusion. Interestingly, even in the pres-
ence of 10 Amol/l DSCG, tissue histamine levels rose during
the first 15 min of global ischemia [28]. The obvious
difficulty in inhibiting histamine release from mast cells
during myocardial ischemia might be due to ATP-depletion,
leading to Ca2 + influx and piecemeal degranulation.
The protracted post-ischemic release of myocardial TNF-
a observed in our experiments is presumably a result of
enhanced TNF-a expression (Fig. 1, insert). The inhibition
of the late phase obtained with ketotifen or DSCG indicates
that mast cell stimulation seems to be vital for initiating this
process. An autocrine stimulation of TNF-a expression has
been described before [29]. Alternatively, as yet unidienti-
fied products of mast-cell degranulation might serve as
trigger for late TNF-a release. Histamine alone obviously
does not suffice.
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 4.3. Role of TACE
Both forms of TACE, the zymogen (100 kDa) and the
mature enzyme (80 kDa), were detected in homogenized rat
heart tissue, although the processed form (lacking the
cysteine switch containing prodomain) was clearly the
predominant one. Thus, there seems to be rather little scope
for oxidative activation of pro-TACE. Furthermore, the ratio
of the 100-kDa to the 80-kDa band did not shift signifi-
cantly towards the smaller species after ischemia, which
argues against acutely enhanced proteolytic processing of
TACE during reperfusion. However, should oxidative or
proteolytic activation of TACE occur only in the small
subset of cardiac mast cells, it would be overlooked if
whole heart homogenates are analysed.
HMC-1 served as model system for cardiac mast cells in
order to better assess the role of oxidative stress in TACE-
activation. Pro-TACE was not only abundant in lysates of
HMC-1; it even predominated over the 80-kDa form. How-
ever, exposure to oxidants did not shift the relationship. Thus,
one can imagine a rapid rise of enzyme activity via oxidation
of the ‘‘cysteine switch’’ as likely alternative to its activation
via conversion by a furin-like protease. Unfortunately, HMC-
1 expressed hardly any TNF-a in the nonstimulated state.
Hence, use was made of the TNF-a-peptide Ac-SLPA-
QAVRSSSR-NH2 as substrate for cleavage. HMC-1 rapidly
degraded the peptide, but not to the TACE-specific hexamer
Ac-SPLAQA, one of two products obtained after incubation
of TNF-a-peptide with recombinant human TACE catalytic
domain [8]. On the other hand, the rate of substrate degra-
dation was increased by addition of 500 Amol/l H2O2 or 50
Amol/l HOCl to the cells and proved susceptible to inhibition
by TAPI-2, but only at 100 Amol/l, at which concentration
TAPI-2 is no longer specific for TACE. One ready explana-
tion for these observations is the existence of (an)other
substrate-degrading activity(ies), similar to but distinct from
TACE. As degradation of the TNF-a-peptide was almost
completely blocked by 1 mmol/l o-phenanthroline, the en-
zyme(s) in question must be (a) metalloproteinase(s). TNF-a-
converting activity has been demonstrated previously for at
least ADAM-10 and MMP-7 and -17 [30–32].
Taken together, our results clearly show that an oxidation-
sensitive mechanism initiates post-ischemic myocardial re-
lease of TNF-a. Data obtained with HMC-1 cells and
myocardial tissue make it unlikely that this is accomplished
via enhanced processing of pro-TACE. In fact, shedding of
TNF-a even seems to be largely independent of TACE,
relying on other oxidatively activated metalloproteinases. In
our heart model, early TNF-a release seems to stem from
mast cell activation. Preliminary data using KitW/KitW/W-v
mice [33], a knockout line with very few myocardial mast
cells, show that these animals lack the early post-ischemic
peak of cytokine release (unpublished data). The later release,
in contrast, requires de novo synthesis of TNF-a, possibly
induced by TNF-a itself and/or intracellular oxidative stress.These conclusions have direct bearing on the situation in the
human heart: After CABG, an absolutely identical time-
course of coronary TNF-a release has been observed, with
an early and a later phase, and both were mitigated by
generating the radical scavenger nitric oxide [34]. Interest-
ingly, a negative correlation exists between the amount of
TNF-a released during the first 5 min of reperfusion and the
cardiac index determined several hours after the intervention
[19]. Owing to the early release of TNF-a, as well as the
inflammatory potential of the cytokine, antioxidative inter-
ventions and mast cell stabilization in general will surely
influence post-ischemic reperfusion damage. While TACE
inhibitors may turn out to be ineffective, mast cell stabilizers
could possess an unexpected potential in this regard.Acknowledgements
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